63930-46-1

Basic information

• Product Name: 1-Propanol, 2-methyl-3-(phenylmethoxy)-, (2S)-
• Synonyms: (-)-(S)-3-benzyloxy-2-methylpropan-1-ol;(2S)-2-methyl-3-(phenylmethoxy)-1-propanol;(S)-3-(benzyloxy)-2-methyl-1-propanol;(2S)-3-benzyloxy-2-methylpropane-1-ol;(S)-2-methyl-3-(benzyloxy)-1-propanol;(2S)-3-(benzyloxy)-2-methylpropan-1-ol
• CAS NO: 63930-46-1
• Molecular Formula: C11H16O2
• Molecular Weight: 180.247
• Mol File: 63930-46-1.mol
• Article Data: 89

Chemical Properties

• CAS DataBase Reference: 1-Propanol, 2-methyl-3-(phenylmethoxy)-, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Propanol, 2-methyl-3-(phenylmethoxy)-, (2S)-(63930-46-1)
• EPA Substance Registry System: 1-Propanol, 2-methyl-3-(phenylmethoxy)-, (2S)-(63930-46-1)

Safety Data

• Hazardous Substances Data: 63930-46-1(Hazardous Substances Data)

Upstream product

• 2163-42-0 2-methyl-1.3-propanediol 
• 100-39-0 benzyl bromide 
• 3587-60-8 Benzyloxymethyl chloride 
• 191105-59-6 (S)-N-propionyl-4-(4-hydroxybenzyl)oxazolidin-2-one 
• 100-52-7 benzaldehyde 
• 5658-46-8 ((2-methylallyloxy)methyl)benzene 
• 108-05-4 vinyl acetate 
• 63930-46-1 3-(benzyloxy)-2-methylpropan-1-ol 
• 100-51-6 benzyl alcohol 
• 102146-10-1 ((R)-3,3-Dimethoxy-2-methyl-propoxymethyl)-benzene 
• 59965-08-1 (S)-(+)-3-N-Phenylcarbamoyloxy-2-methyl-propansaeure 
• 103-71-9 phenyl isocyanate 
• 59965-09-2 (R)-3-Hydroxy-2-methyl-1-propylcarbanilat 
• 78479-16-0 (2S,3R)-threo-3-methylbutane-1,2,4-triol 4-benzyl ether 

Downstream Products

• 63930-49-4 (R)-3-(benzyloxy)-2-methylpropan-1-ol 
• 141885-91-8 (S)-3-benzyloxy-2-methylpropyl acetate 
• 141885-91-8 (R)-3-benzyloxy-2-methylpropyl acetate 
• 64316-89-8 (S)-3,3,3-Trifluoro-2-methoxy-2-phenyl-propionic acid 3-benzyloxy-2-methyl-propyl ester 
• 74130-31-7 3-(benzyloxy)-2-methylpropanal 
• 64316-89-8 3,3,3-Trifluoro-2-methoxy-2-phenyl-propionic acid (R)-3-benzyloxy-2-methyl-propyl ester 
• 875631-27-9 C₁₇H₂₀OS 
• 920520-63-4 (2S)-2-[(methyldecyloxy)methyl]benzene 
• 920520-62-3 (2R)-1-benzyloxy-2-methyl-3-(phenylsulfonyl)decane 
• 127733-22-6 (2R)-1-benzyloxy-2-methyl-3-(phenylsulfonyl)propane 
• 932406-80-9 ((S)-2-Methyl-dodecyloxymethyl)-benzene 
• 153628-61-6 (Z)-(4R,5S,6R)-7-Benzyloxy-2,4,6-trimethyl-hept-2-ene-1,5-diol 
• 153628-62-7 2,2-Dimethyl-propionic acid (Z)-(4R,5S,6R)-7-benzyloxy-5-hydroxy-2,4,6-trimethyl-hept-2-enyl ester 
• 157542-30-8 (2R,3S)-2-((R)-2-Benzyloxy-1-methyl-ethyl)-3,5-dimethyl-2,3-dihydro-pyran-4-one 

Relevant articles and documents

Stereoselective 1,5-rearrangement of vinylketene-N,O-acetals: Novel vinylogous Ferrier reaction

Vinylketene-N,O-acetals underwent Lewis acid-induced 1,3- or 1,5-rearrangement to afford the corresponding C-alkylated products. 1,5-Rearrangement proceeded predominantly in dichloromethane, and it is quite interesting to achieve an unprecedented high degree of asymmetric induction in such a remote position. Crossover experiments indicated that the reaction proceeded through an ion pair intermediate.

Progress toward the total synthesis of mirabalin isomers

Key fragments of the cytotoxic marine macrolide mirabalin have been synthesized, by using a flexible strategy based on asymmetric reductions to control the hydroxy- and carbamate-bearing stereocenters. In particular, ruthenium or rhodium-mediated asymmetric hydrogenation and transfer hydrogenation were used in combination with a dynamic kinetic resolution to control two contiguous stereocenters in a single step.

Substituted heteroaryl compound and composition thereof, and uses of substituted heteroaryl compound and composition thereof

The present invention provides a substituted heteroaryl compound and a composition thereof, and uses of the substituted heteroaryl compound and the composition, wherein the compound is a compound represented by a formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound represented by the formula (I). The present invention further provides a pharmaceutical composition containing the compound, wherein the pharmaceutical composition can regulate activity of protein kinases, particularly Aurora kinases and JAK kinases, and can be used for prevention, treatment, therapy and alleviation of protein kinases, particularly Aurora kinases and JAK kinase activity mediated diseases or disorders.